Gastroenterologia Japonica

, Volume 25, Issue 2, pp 244–248 | Cite as

Specific cytotoxic effect of neocarzinostatin conjugated to monoclonal antibody A7 on human pancreatic carcinoma

  • Eigo Otsuji
  • Toshio Takahashi
  • Toshiharu Yamaguchi
  • Nozomi Yamaguchi
  • Jiro Imanishi
Liver and Pancreas


The anti-cancer drug neocarzinostatin (NCS) was bound covalently to the monoclonal antibody A7 to form the conjugate A7-NCS. This antibody was produced by fusing the spleen cells of a mouse immunized against human colonic carcinoma with murine myeloma cells and reacts with a high percentage of human pancreatic carcinoma cell lines and with no normal human pancreas tissue by immunoperoxidase staining. The cytotoxic effect of A7-NCS was tested by measuring the inhibition of3H-thymidine incorporation into human pancreatic carcinoma cells. The A7-NCS was approximately 2.7 times as effective as free NCS against human pancreatic carcinoma cells which reacted with the monoclonal antibody A7. A7-NCS had almost the same cytotoxicity a free NCS on human pancreatic carcinoma cells which did not react with the monoclonal antibody A7. A7-NCS appeared to be potentially useful as a conjugate for immunotargeting chemotherapy against pancreatic carcinoma.

Key words

immunoconjugate immunotargeting chemotherapy monoclonal antibody A7 neocarzinostatin pancreatic carcinoma 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aoki K, Ogawa H: J Cancer of pancreas, international mortality trends. World Health Statistical Rep. 1978;31:2–27Google Scholar
  2. 2.
    David L, Levin MD, Roger R, et al: Demographic characteristics of cancer of the pancreas: Mortality, incidence, and survival. Cancer 1981 ;47:1456–1468Google Scholar
  3. 3.
    Köhler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495–497PubMedCrossRefGoogle Scholar
  4. 4.
    Takahashi T, Yamaguchi T, Kitamura K, et al: Clinical application of monoclonal antibody-drug conjugates for immunotargeting chemotherapy of colorectal carcinoma. Cancer 1988;61:881–888PubMedCrossRefGoogle Scholar
  5. 5.
    Fukuda K: The study of targeting chemotherapy against the gastrointestinal cancer (the preparation of anticancer drug-monoclonal antibody conjugate and the investigation about its biological activity). Akita J Mcd 1985;12:451–468Google Scholar
  6. 6.
    Otsuji E. Yamaguchi N, Takahashi T. et al: Reactivity of monoclonal antibody A7 and other tumor markers with human pancreatic carcinoma cell lines and their spent media. J Clin Exp Med 1989;148:753–754Google Scholar
  7. 7.
    Yamaguchi N, and Kawai K: Acid protease from human pancreatic carcinoma cell line HPC-YT into serum-free, chemically defined medium. Cancer Res 1986;46:5353–5359PubMedGoogle Scholar
  8. 8.
    Siroeda O, Yamaguchi N, Kawai K: Stimulation of low density lipoprotein receptor activity by conditioned medium from human cancer cell line. Cancer Res 1987;47:4630–4633Google Scholar
  9. 9.
    Kotanagi H, Takahshi T, Masuko T, et al: A monoclonal antibody against human colon cancers. Tohoku J exp Med 1986;148:353–360PubMedGoogle Scholar
  10. 10.
    Takahashi T, Sakita M, Yamaguchi T, et al: Clinical application of monoclonal antibody-drug conjugates for colorectal carcinoma. Jpn J Cancer Chmothcr 1988;15:1703–1709Google Scholar
  11. 11.
    Su-ming HSU. Raine L, and Fanger H: Use of Avidin-biotinperoxidase complex (ABC) in immunoperoxidasc techniques. J Histochem Cytochem 1981;29:577–580Google Scholar
  12. 12.
    Masuoka K, Maeda M, Tsujii A: Fluorophotometric enzyme assay of neocarzinostatin using peroxidase as a label. Chem Pharm Bull 1980;28:1864–1868Google Scholar
  13. 13.
    Ehrlich P: In: Collected studies on immunity. John Wiley and Sons. Inc., New York. 1960;442–447Google Scholar
  14. 14.
    Isliker H, Cerottinin JC, Jaton JC, et al: G. Specific and nonspecific fixation of plasma protein in tumors. In chemotherapy of Cancer. Elsevier Publishing Co., Amsterdam. 1969;278–288Google Scholar
  15. 15.
    Hurwitz E, Levy R, Marson R. et al: The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities. Cancer Res 1975;35:1175–1181PubMedGoogle Scholar
  16. 16.
    Levy R, Hurwitz E, Marson R. et al: The specific cytotoxic effects of daunomycin conjugated to antitumor antibodies. Cancer Res 1975;35:1182–1186PubMedGoogle Scholar
  17. 17.
    Arnon R. Sela M: In vitro and in vivo efficacy of conjugates of daunomycin with anti-tumor antibodies. Immunological Rev 1982;62:5–27CrossRefGoogle Scholar
  18. 18.
    Maeda H: Neocarzinostain in cancer chemotherapy. Anticancer Res 1981;1:175–186PubMedGoogle Scholar
  19. 19.
    Sakamoto S, Ogata J, Ikegami K, et al: Chemotherapy for bladder cancer with neocarzinostatin: Evaluation of systemic administration. Eur J Cancer 1980; 16:103–113PubMedGoogle Scholar
  20. 20.
    Hiraki K, Kamimura O: Neocarzinostatin: Use approche nouvelle dans la chemiotherapie des leucemia aigues Nouv. Revue Francaise d’ Hematologie 1973;13:445–451Google Scholar
  21. 21.
    Yamanouchi Pharmaceutical Co. Ltd.: Summary of national cummulative data on neocarzinostatin treatment for cancers in digestive organs in Japan. June, 1980.Google Scholar
  22. 22.
    Napier MA, Holmquist B. Strydom DJ. et al: Neocarzinostatin: Spectral characterization and separation of a non-protein. Biochem Biophys Res Commun 1979;89:635–642PubMedCrossRefGoogle Scholar
  23. 23.
    Napier MA, Kappen LS and Goldberg IH: Effect of nonprotein chromophorc removal on neocarzinostatin action. Biochem 1980;19:1767–1773CrossRefGoogle Scholar
  24. 24.
    Ohtsuki K, Ishida N: The biological effect of a nonprotein component removed from neocarzinostatin (NCS). J antibiot 1980;33:744–750PubMedGoogle Scholar
  25. 25.
    Jung G, Kohnlein W, Luders G: Biological activity of the antitumor protein neocarzinostatin coupled to a monoclonal antibody by N-succinimidyl 3-(2-pyridyldithio)-protionate. Biochem Biophys Res Commun 1981;101:599–606CrossRefGoogle Scholar
  26. 26.
    d’Lazarus H, Raso V and Samy TSA: In vitro inhibition of human leukemic cells (CCRF-CEM) by agarose-immobilized neocarzinostatin. Cancer Res 1977;37:3731Google Scholar
  27. 27.
    Kimura I, Ohnoshi T. Tsubota T. et al: Production of tumor antibody-neocarzinostatin (NCS) conjugate and its biological activities. Cancer Immunol Immunother 1980;7:235–242CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Gastroenterology 1990

Authors and Affiliations

  • Eigo Otsuji
    • 1
  • Toshio Takahashi
    • 1
  • Toshiharu Yamaguchi
    • 1
  • Nozomi Yamaguchi
    • 2
  • Jiro Imanishi
    • 2
  1. 1.First Department of SurgeryKyoto Prefectural University of MedicineKyotoJapan
  2. 2.Department of MicrobiologyKyoto Prefectural University of MedicineKyotoJapan

Personalised recommendations